

## **CURRICULUM VITAE**

### **INFORMAȚII PERSONALE**

NUME- DROCAȘ

PRENUME- IOAN ANDREI

DATA ȘI LOCUL NAȘTERII-13.04.1985 PITESTI, ARGEȘ, ROMÂNIA

ADRESA- CRAIOVA, STR. SPANIA, 8MAN, SC. 2 AP. 11

TELEFON- 004-0785216968

ADRESA DE E-MAIL- [andrei\\_drocas@yahoo.com](mailto:andrei_drocas@yahoo.com)

### **EDUCAȚIE**

2015- prezent- Medic Specialist Urolog, Spitalul Clinic Filantropia, Craiova

2013- prezent- Doctorand în cadrul Universității de Medicină și Farmacie Craiova

2010-2014- Medic rezident Urologie, Clinica de Urologie, Spitalul Clinic Județean de Urgență, Craiova

2004-2009- Universitatea de Medicina și Farmacie Craiova

2000-2004- Colegiul Național Dinicu Golescu, Cîmpulung-Muscel

### **COMPETENȚE PERSONALE**

FRANCEZĂ- NIVEL MEDIU

ENGLEZĂ- NIVEL BUN

GERMANĂ- NIVEL SCĂZUT

### **PARTICIPARE CONFERINȚE, CURSURI**

**2015**-Congresul Național de Urologie

-Congresul European de Urologie

**2014**-Congresul Național de Urologie

-Congresul European de Urologie

**2013**-Congresul Național de Urologie

-Școala de vară a urologiei - hands on training on endourology

**2012**-Congresul Național de Urologie

-Școala de vară a urologiei

**2011**-Congresul național de urologie

**2010**-Congresul Național de Urologie

**Membru** - Asociația Română de Urologie (ARU) -2010

-Asociația Europeană de Urologie (EAU) - 2010

## **PROIECTE DE CERCETARE**

2015- Certificat Good Clinical Practice

2013- Investigator secundar -“A Phase III Arm Study to Evaluate the Efficacy,Safety and Local Tolerability of a Subcutaneous 3-Month Formulation of Triptorelin Pamoate(11,25 mg) in Patients with Locally Advanced or Metastatic Prostate Cancer”

- Investigator secundar:« Efectiveness and Safety of Silodosin in the Treatment of LUTS in Patients with Benign Prostatic Hyperplasia- A EUROPEAN PHASE IV CLINICAL STUDY »

2011- Investigator secundar « A Randomized,Double-Blind,Factorial,Parallel-Group,Active and Placebo-Controlled,Multicenter Dose-Ranging Study to Evaluate the Efficacy,Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder » PHASE II CLINICAL STUDY

2010- Certificat Good Clinical Practice

- Investigator secundar: « URS- a prospective international observational study on indications and perioperative outcomes ;study developed by Clinical Research Office of the Endourological Society (CROES), Chairman Prof. Jean de la Rosette. »

## PUBLICAȚII

1. O. DRĂGOESCU, P. TOMESCU, A. PĂNUȘ, **A. DROCAȘ**, C. MARIA, M. ENACHE, Adjuvant Treatment of Intermediate Risk Non-muscle Invasive Bladder Cancer, *Current Health Sciences Journal* 2014, 40(1):47-50
2. ALEX EMILIAN STEPAN, DANIEL PIRICI, MARIA BĂLĂȘOIU, MARIUS BOGDAN NOVAC, **ANDREI IOAN DROCAȘ**, RALUCA NICULINA CIUREA, DESDEMONA STEPAN, DAN IONUȚ GHEONEA, CRISTIANA EUGENIA SIMIONESCU), E-cadherin/CD44 immunophenotype in the epithelial–mesenchymal transition of bladder urothelial carcinomas, *Rom J Morphol Embryol* 2015, 56(1):85–91
3. Octavian DRĂGOESCU, **Andrei Ioan DROCAȘ**, George MITROI, Cosmin MITITELU, Alice GĂMAN, Anca UNGUREANU, Paul TOMESCU, NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCE RISK FACTORS, *Research and Science Today* 2016, 1(11):139-46
4. **Andrei Drocaș**, Paul Tomescu, George Mitroi, Octavian Drăgoescu, Claudiu Mărgăritescu, Alex Emilian Stepan, Valeriu Șurlin, Ștefania Crăițoiu, Ileana Drocaș, Anca Ungureanu, Alice Găman, Adriana Turculeanu, Cristiana Eugenia Simionescu, The cadherin switch assessment in the epithelial-mesenchymal transition of urothelial bladder carcinomas, *Rom J Morphol Embryol* 2016, xyz-xyz
5. ANCA UNGUREANU, ALICE ELENA GAMAN, ADRIANA TURCULEANU, MIHAELA MITROI, **A.I. DROCAS**, MARIA DOBRITOIU, D.O. ALEXANDRU, CORINA VASILE, Incidence and Antifungal Susceptibility of *Candida Albicans* Infections, *Current Health Sciences Journal* 2016, 42(2):164-8
6. Anca UNGUREANU, Alice Elena GĂMAN, **Andrei Ioan DROCAȘ**, Eugen ȚIERANU, Maria DOBRIȚOIU, THE INFLUENCE OF STEATOSIS AND CONJUGATE FACTORS OF RESPONSE TO ANTIVIRAL TREATMENT IN CRONIC HEPATITIS C, *Research and Science Today* 2016, 1(11):147-55